sponsored
PatientsVille.com Logo

PatientsVille

Glucophage Medical Research Studies

Up-to-date List of Glucophage Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Glucophage Medical Research Studies

Rank Status Study
1 Recruiting Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin IR;   Drug: Saxagliptin;   Drug: Saxagliptin/Metformin XR FDC;   Drug: Metformin XR
Outcome Measures: Maximum observed plasma concentration (Cmax) of Saxagliptin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Saxagliptin;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of Saxagliptin;   Maximum observed plasma concentration (Cmax) of 5-hydroxy Saxagliptin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of 5-hydroxy Saxagliptin;   Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of 5-hydroxy Saxagliptin;   Maximum observed plasma concentration (Cmax) of Metformin;   Area under the plasma concentration-time curve from time zero to 24 hours [AUC(0-24)] of Metformin;   Area under the plasma concentration-time curve from time zero to 12 hours [AUC(0-12)] of Metformin;   Safety: based on medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests;   Formulation swallowability of Saxagliptin-Metformin FDC tablet, Glucophage® IR tablet and Glucophage® XR tablet
2 Not yet recruiting Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Low Metformin;   Drug: Metformin;   Drug: Mid Metformin;   Drug: High Metformin
Outcome Measures: Change In Fasting Plasma Glucose;   Gastrointestinal Effects;   Change in Baseline-Corrected Plasma Glucose and Insulin Area Under The Concentration Curves;   Change in Insulin Secretory Rates;   Change in Fasting Plasma Lipids;   Change in HbA1c;   Change in HOMA-IR;   Change In 7-Point Glucose Profiles;   Change In Serial Blood Glucose Concentrations;   Safety and Tolerability
3 Recruiting Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Outcome Measures: Mean change in glycosylated hemoglobin (HbA1c) from baseline to Week 24;   Mean change in fasting plasma glucose (FPG) from baseline to Week 24;   Mean change in Mean Daily Glucose (MDG) from baseline to Week 24;   Percent of subjects with HbA1c <7%
4 Recruiting Efficacy and Safety of Alogliptin and Metformin Fixed-dose Combination in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus
Interventions: Drug: Alogliptin;   Drug: Metformin HCl;   Drug: Alogliptin and Metformin fixed-dose combination (FDC);   Drug: Alogliptin placebo;   Drug: Metformin placebo;   Drug: Alogliptin and metformin FDC placebo
Outcome Measures: Change From Baseline to Week 26 (or Early Termination) in Glycosylated Hemoglobin (HbA1c);   Change From Baseline in HbA1c Over Time;   Change From Baseline in Fasting Plasma Glucose Over Time;   Time to hyperglycemic rescue event;   Percentage of Participants Meeting Rescue Criteria;   Percentage of Participants With Marked Hyperglycemia;   Change From Baseline in Body Weight Over Time;   Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%;   Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0%;   Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.0%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%;   Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0%
5 Recruiting PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Conditions: Diabetes Mellitus, Non-Insulin-Dependent;   Hypertriglyceridemia
Interventions: Drug: Metformin Eicosapentaenoate;   Drug: Metformin HCl and Vascepa
Outcome Measure: AUC following single and repeat single oral administration of metformin eicosapentaenoate, metformin hydrochloride and Vascepa
6 Recruiting Bioequivalence of a Medium, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects.
Condition: Healthy
Interventions: Drug: Linagliptin;   Drug: Metformin;   Drug: Linagliptin/Metformin FDC
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of metformin in plasma;   Area under the concentration-time curve of linagliptin and metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of metformin in plasma
7 Recruiting Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis
Conditions: Polycystic Ovary Syndrome;   Disorder of Glucose Regulation
Interventions: Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin-Metformin XR
Outcome Measures: Fasting and 2 hour glucose levels after glucose load;   ß-cell compensatory function;   Surrogate measures of insulin sensitivity and secretion;   Cardiometabolic risk factors;   Free androgen index
8 Unknown  Reducing Antipsychotic-Induced Weight Gain in Children With Metformin
Conditions: Obesity;   Weight Gain;   Psychotropic Induced Weight Gain
Intervention: Drug: Metformin
Outcome Measures: Change in weight;   Weight trajectory based on length of intervention and factors that predict response to Metformin
9 Recruiting Bioequivalence of a Low, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects
Condition: Healthy
Interventions: Drug: Linagliptin;   Drug: Linagliptin/Metformin ER FDC;   Drug: Metformin ER
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of metformin in plasma;   Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of metformin in plasma
10 Recruiting Bioequivalence of a High, Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release in Healthy Subjects
Condition: Healthy
Interventions: Drug: Linagliptin/Metformin ER FDC;   Drug: Linagliptin;   Drug: Metformin ER
Outcome Measures: Area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 hours (AUC0-72);   Maximum measured concentration of linagliptin in plasma (Cmax);   Area under the concentration-time curve of metformin in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz);   Cmax of metformin in plasma;   Area under the concentration-time curve of metformin in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf);   AUC0-inf of linagliptin in plasma
11 Recruiting Study of Metformin With Simvastatin for Men With Prostate Carcinoma
Condition: Prostate Carcinoma
Interventions: Drug: Metformin;   Drug: Simvastatin
Outcome Measures: Efficacy, as measured by an improvement in PSA doubling time (PSADT) between baseline and 6 months, of the combination of metformin plus simvastatin in patients with recurrent prostate cancer following definitive treatment.;   Time to protocol-specified event for men treated with the combination of metformin plus simvastatin.;   Pattern of change in log PSA levels and PSA velocity over time during treatment with metformin plus simvastatin.;   Associations between changes in metabolic parameters (fasting glucose/insulin/lipid panel/leptin/adiponectin and others) with the pattern of change in log PSA levels.
12 Recruiting A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: metformin alone (Arm A);   Drug: metformin (Arm B);   Drug: rapamycin (Arm B)
Outcome Measure: safety and feasibility
13 Recruiting Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects
Condition: Healthy
Interventions: Drug: metformin;   Drug: BI 187004
Outcome Measures: AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004;   AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t) for metformin;   Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for BI 187004;   Cmax,ss (Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t) for metformin
14 Not yet recruiting Evaluating of Pharmacokinetic Profile of BCWP_C001 and Co-administration of Rosuvastatin and Metformin
Condition: Healthy
Interventions: Drug: Rosuvastatin and Metformin SR(Fed);   Drug: BCWP_C001(Fasted);   Drug: BCWP_C001(Fed)
Outcome Measures: Rosuvastatin, Metformin Cmax, AUClast;   N-desmethyl rosuvastatin Cmax;   N-desmethyl rosuvastatin AUClast;   N-desmethyl rosuvastatin AUCinf;   Rosuvastatin, N-desmethyl rosuvastatin, Metformin AUCinf;   Rosuvastatin, N-desmethyl rosuvastatin, Metformin Tmax;   Rosuvastatin, N-desmethyl rosuvastatin, Metformin t1/2;   Rosuvastatin, N-desmethyl rosuvastatin, Metformin Vz/F;   Rosuvastatin, N-desmethyl rosuvastatin, Metformin CL/F
15 Recruiting Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)
Condition: Polycystic Ovary Syndrome
Intervention: Drug: Metformin
Outcome Measures: Change in Insulin Sensitivity (SI) after 3 Months of Metformin Therapy;   Change in Peripheral Flow-Mediated Vasodilatation after 3 Months of Metformin Therapy
16 Recruiting Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk
Condition: Breast Cancer Prevention
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: change from baseline in breast density at 6 and 12 months;   change from baseline in serum insulin levels at 6 and 12 months;   change from baseline in serum IGF-1 to IGFBP-3 ratio at 6 and 12 months;   change from baseline in serum testosterone levels at 6 and 12 months;   change from baseline in serum leptin to adiponectin ratio at 6 and 12 months;   change from baseline in body weight at 6 and 12 months;   change from baseline in waist circumference at 6 and 12 months;   change from baseline in serum IGF-2 levels at 6 and 12 months
17 Not yet recruiting A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.
Condition: Prostatic Neoplasm
Interventions: Drug: Metformin;   Drug: Placebo
Outcome Measures: Mean body weight at 12 months of follow-up;   Prevalence and incidence of Metabolic Syndrome
18 Recruiting Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets
Condition: Healthy
Interventions: Drug: 1 tablet Empagliflozin/2 tablets Metformin XR;   Drug: 10 mg Empagliflozin/1000 mg Metformin XR;   Drug: 1 tablet 10 mg Empagliflozin/3 tablets Metformin XR;   Drug: 2 tablets 5 mg Empagliflozin/750 Metformin XR
Outcome Measures: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point), for empagliflozin and metformin;   Cmax (maximum measured concentration of the analyte in plasma, for empagliflozin and metformin;   AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity), for empagliflozin and metformin
19 Recruiting A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine
Outcome Measures: Change from baseline in hemoglobin A1c (A1C);   Number of participants who experienced at least one adverse event;   Number of participants who discontinued study drug due to an adverse event
20 Recruiting Exercise and Metformin in Colorectal and Breast Cancer Survivors
Conditions: Colorectal Cancer;   Breast Cancer
Interventions: Behavioral: Exercise training;   Drug: Exercise training plus metformin;   Drug: Metformin;   Other: Educational information
Outcome Measures: Determine whether supervised exercise training alone and metformin, either alone or in combination can decrease fasting insulin level from baseline to 3 months in patients who completed standard therapy for stage I-III colorectal or breast cancer.;   Compare changes in other insulin-related biomarkers;   Explore for an interaction effect in addition to an additive effect of exercise and metformin in reducing fasting insulin level over the 3 month intervention;   Compare changes in body composition by treatment arm;   Compare change in pro-inflammatory markers potentially related to insulin resistance by treatment arm;   Compare self-directed change in diet quality by treatment arm

These studies may lead to new treatments and are adding insight into Glucophage etiology and treatment.

A major focus of Glucophage research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Glucophage